- Home
- ADAP vs GDTC Comparison
ADAP vs GDTC Comparison
Compare ADAP & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- GDTC
- Stock Information
- Founded
- ADAP 2008
- GDTC 2018
- Country
- ADAP United Kingdom
- GDTC Singapore
- Employees
- ADAP N/A
- GDTC N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- GDTC Health Care
- Exchange
- ADAP Nasdaq
- GDTC Nasdaq
- Market Cap
- ADAP 21.3M
- GDTC 21.5M
- IPO Year
- ADAP 2015
- GDTC 2023
- Fundamental
- Price
- ADAP $0.06
- GDTC $1.85
- Analyst Decision
- ADAP Hold
- GDTC Buy
- Analyst Count
- ADAP 6
- GDTC 1
- Target Price
- ADAP $1.02
- GDTC $5.00
- AVG Volume (30 Days)
- ADAP 89.0M
- GDTC 8.7K
- Earning Date
- ADAP 08-13-2025
- GDTC 01-01-0001
- Dividend Yield
- ADAP N/A
- GDTC N/A
- EPS Growth
- ADAP N/A
- GDTC N/A
- EPS
- ADAP N/A
- GDTC N/A
- Revenue
- ADAP $65,084,999.00
- GDTC $368,838.00
- Revenue This Year
- ADAP N/A
- GDTC $5.37
- Revenue Next Year
- ADAP $52.35
- GDTC N/A
- P/E Ratio
- ADAP N/A
- GDTC N/A
- Revenue Growth
- ADAP N/A
- GDTC N/A
- 52 Week Low
- ADAP $0.05
- GDTC $1.20
- 52 Week High
- ADAP $1.33
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- ADAP 29.42
- GDTC 47.67
- Support Level
- ADAP $0.05
- GDTC $1.65
- Resistance Level
- ADAP $0.09
- GDTC $1.88
- Average True Range (ATR)
- ADAP 0.01
- GDTC 0.05
- MACD
- ADAP 0.00
- GDTC 0.01
- Stochastic Oscillator
- ADAP 7.21
- GDTC 87.28
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.